Form 10-Q Voyager Therapeutics, For: Mar 31
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 6/12/2026
- Wall Street ends higher as SpaceX's market debut dominates
- SpaceX prices historic IPO at $135/share in largest ever new listing
- 'Ocean of opportunity': Wolfe initiates SpaceX at Buy ahead of historic IPO
- UBS cuts gold price forecasts on delayed Fed easing outlook
- Brent falls to lowest since March on expected peace deal
- NASDAQ adds five companies to NASDAQ-100 index in quarterly rebalance
- Adobe CFO Dan Durn to depart company in June 2026
- Oppenheimer Starts SpaceX (SPCX) at Outperform, PT $190, 'space infrastructure appears structurally advantaged'
- Pentagon reportedly locked down, hazmat teams responding
- Super Micro Computer establishes $1.25 billion stock sale agreement
Voyager Therapeutics (VYGR) PT Lowered to $8 at Wedbush
May 14, 2024 6:47 AM EDTWedbush analyst Laura Chico lowered the price target on Voyager Therapeutics (NASDAQ: VYGR) to $8.00 (from $10.00) while maintaining a Neutral rating.
The analyst comments "Remain Neutral rated on VYGR, new $8 target. On the heels of the AGCST meeting, the 1Q24 VYGR update... More
